Buscar
Mostrando ítems 1-4 de 4
Heterologous hyperimmune polyclonal antibodies against SARS-COV-2: A broad coverage, affordable, and scalable potential immunotherapy for Covid-19
(2021-09)
The emergence and dissemination of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and the resulting COVID-19 pandemic triggered a global public health crisis.
Although several SARS-CoV-2 vaccines have ...
Preclinical evaluation of the efficacy of antivenoms for snakebite envenoming: State-of-the-art and challenges ahead
(2017-05)
Animal-derived antivenoms constitute the mainstay in the therapy of snakebite envenoming. The efficacy of antivenoms to neutralize toxicity of medically-relevant snake venoms has to be demonstrated through meticulous ...
Delayed oral LY333013 rescues mice from highly neurotoxic, lethal doses of Papuan Taipan (Oxyuranus scutellatus) venom
(2018)
There is an unmet need for economical snakebite therapies with long shelf lives
that are effective even with delays in treatment. The orally bioavailable, heat-stable, secretory
phospholipase A2 (sPLA2) inhibitor, LY333013, ...
In vitro Characterization of Anti-SARS-CoV-2 Intravenous Immunoglobulins (IVIg) Produced From Plasma of Donors Immunized With the BNT162b2 Vaccine and Its Comparison With a Similar Formulation Produced From Plasma of COVID-19 Convalescent Donors
(2022)
Despite vaccines are the main strategy to control the ongoing global COVID-19
pandemic, their effectiveness could not be enough for individuals with
immunosuppression. In these cases, as well as in patients with ...